Newsroom | 4962 results

OTSU, Japan--(BUSINESS WIRE)--Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary a...

SAN DIEGO--(BUSINESS WIRE)--SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has published a peer-reviewed article in the International Journal of Molecular Sciences on best practices for the clinical use of genome-wide association study (GWAS) data. The article provides guidance for integrating imputed genetic information into healthcare in a way that supports accuracy, transparency, and clinical utility. Co-authored by...

PASADENA, Calif.--(BUSINESS WIRE)--Ophidion, Inc., a biotechnology company pioneering non-invasive delivery of gene-silencing and large-molecule therapeutics to the brain, and Neuronasal, Inc., a clinical-stage company advancing patented nose-to-brain delivery of therapeutics, today announced a strategic partnership to co-develop multiple therapeutic candidates targeting key pathways in Parkinson’s disease as well as the treatment of obesity and diabetes. Under the agreement, Ophidion will depl...

ATLANTA--(BUSINESS WIRE)--Nephrodite, Inc., a medical device company developing an implantable, continuous renal replacement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s Holly™ implantable, continuous dialysis system. The designation recognizes Holly as a novel, transformative therapy addressing end-stage kidney disease (ESKD) which affects more than 850,000 people in the U.S., costing more than $50 billion...

DUBLIN--(BUSINESS WIRE)--The "Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering. The global diabetic neuropathy market is expected to grow with a CAGR of 5% from 2025 to 2031. The major drivers for this market are the increasing prevalence of diabetes worldwide, the rising awareness about neuropathic disorders, and the growing demand for effective pain management. The future of the global diabetic neuropathy...

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, the leader in Cellular RPM™ and the nation’s most trusted source of patient-generated vital health data, announced exceptional momentum in its integration and partnership with eClinicalWorks, one of the largest AI-powered ambulatory EHR platforms in the country. So far in 2025, the partnership has driven a 107% year-over-year increase in active Smart Meter devices used by eClinicalWorks (eCW) providers — now surpassing 25,000 active devices in the mark...

MCLEAN, Va.--(BUSINESS WIRE)--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company’s Zepbound® will be the first medication available on its platform. Employers will be able to contribute non-taxed dollars to lower their employees’ out-of-pocket costs for branded therapies, starting with obesity management med...

CHICAGO & NEW YORK--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, under its Industry Discovery and Development Partnership (IDDP) program to advance a pancreatic beta cell therapy targeting T1D using its Cellgorithm platform technology. “The daily burden for those living with t...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), société biopharmaceutique au stade clinique développant des traitements innovants pour les maladies chroniques graves à physiopathologie métabolique, notamment metabolic dysfunction-associated steatohepatitis (MASH) et les maladies métaboliques rares (la « Société »), annonce aujourd'hui ses résultats financiers consolidés semestriels résumés pour la période close le 30 juin 2025 et fait le point sur les...

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces today its condensed consolidated half-year financial results for the period ended June 30, 2025 and provides an update on recent events ahead of its a...